Myelodysplastic syndromes remain a group of neoplasias of difficult characterisation and even more difficult and frustrating clinical management, despite the increasing availability of treatment options. In The Lancet Oncology, Uwe Platzbecker and collegues¹ have led a clinical study that has not only potentially opened new avenues for treatment of lower risk anaemic patients with myelodysplastic syndrome, but also has implications for the understanding of the biology of myelodysplastic syndrome.

中文翻译：

---

在骨髓增生异常综合症中战胜贫血：向前迈出的又一步

尽管治疗选择的可用性越来越高，但骨髓增生异常综合征仍然是一组肿瘤，其特征在于困难，甚至临床治疗也更加困难和令人沮丧。在《柳叶刀肿瘤》杂志中，Uwe Platzbecker和同事¹领导了一项临床研究，该研究不仅可能为治疗低危贫血性骨髓增生异常综合症患者开辟新途径，而且对理解骨髓增生异常综合症的生物学意义也很重要。